DATANG POWER (00991) stock trading experiences abnormal fluctuations while production and operation activities remain normal.
Datang Power (00991) announced that on May 11th and May 12th, 2026, the company's stock has experienced a cumulative deviation in closing prices for two consecutive trading days, exceeding 20%. According to relevant provisions of the "Shanghai Stock Exchange Trading Rules", this is considered abnormal volatility in stock trading.
Datang Power (00991) announced that on May 11th and May 12th, 2026, the company's stock price deviated by more than 20% for two consecutive trading days, which is considered abnormal stock price fluctuations according to the relevant rules of the Shanghai Stock Exchange.
The company's stock price has increased by 61.06% from May 6th, 2026 to May 12th, 2026, in five consecutive trading days. From May 6th to May 12th, the company's stock has closed at the limit-up price for five consecutive trading days. The turnover rate in the past five trading days since May 6th were 2.66%, 2.69%, 9.81%, 2.25%, and 5.51%, which are higher than the company's historical turnover rate, indicating higher trading risks. The company's stock price has increased significantly in the short term, deviating from the performance of the Shanghai Composite Index and the industry index.
Through self-inspection, the company's production and operation activities are normal, with no significant changes in daily operations. There have been no major adjustments in market environment or industry policies, and production costs, sales, and other factors have not experienced significant fluctuations, indicating normal internal production and operation order. The board of directors and senior management of the company are performing their duties normally.
After self-inspection and confirmation with the company's controlling shareholder and actual controller, as of the date of this announcement, apart from information that has been publicly disclosed on designated media, there are no major issues affecting the abnormal fluctuations in the company's stock price; there are no major asset restructuring, share issuance, major transaction events, business restructuring, share repurchases, equity incentives, bankruptcy reorganization, major business cooperation, introduction of strategic investors, and other major matters involving the company currently being planned.
The board of directors confirms that the company has not failed to disclose any information that should have been disclosed according to the rules of the Shanghai Stock Exchange for stock listing or any related planning, discussions, intentions, agreements, and has not received any information that may have a significant impact on the trading price of the company's stock and its derivatives.
Related Articles

ZYLOXTB(02190) spent approximately HKD 1.1362 million to repurchase 51,000 shares on May 12th.

PW MEDTECH (01358) spent 992,000 Hong Kong dollars to repurchase 841,000 shares on May 12th.

CIG Shanghai (06166) will distribute a final dividend of $0.28 per share on June 25th.
ZYLOXTB(02190) spent approximately HKD 1.1362 million to repurchase 51,000 shares on May 12th.

PW MEDTECH (01358) spent 992,000 Hong Kong dollars to repurchase 841,000 shares on May 12th.

CIG Shanghai (06166) will distribute a final dividend of $0.28 per share on June 25th.

RECOMMEND

Two Mainland Accounting Firms Approved for H‑Share Audits, Lowering Listing Costs and Deepening Mainland–Hong Kong Market Integration**The Ministry of Finance, the CSRC, and Hong Kong’s Accounting and Financial Reporting Council have approved two additional mainland accounting firms—RSM China and ShineWing—to conduct H‑share audit work, marking the first expansion of the list since 2010.
11/05/2026

HKEX Tightens Rules on Auditor Dismissals as Sudden “Audit Firm Switches” Raise Governance Concerns
11/05/2026

The Chip Stock Frenzy Is Still Accelerating
11/05/2026


